期刊文献+

多西他赛联合顺铂化疗与三维适形放疗同步治疗局部晚期非小细胞肺癌的临床研究 被引量:23

Docetaxel plus Cisplatin Chemotherapy with Concurrent Three Dimensional-Conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
暂未订购
导出
摘要 目的:探讨多西他赛加顺铂化疗同步三维适形放射治疗(three dimensional-conformal radiotherapy3DCRT)的近期疗效、生存期及生活质量。方法:198例局部晚期非小细胞肺癌患者非随机分2组,化疗与放疗序贯组,化疗与放疗同步组。2组病例均采用3DCRT计划,照射剂量70~74Gy,2~2.5Gy/次,3次/周。同步组:102例,多西他赛40mg/m2d1、顺铂30mg/m2d1,在放射治疗开始时同步进行,每周1次,共用4~5次。序贯组:96例,多西他赛60mg/m2d1、顺铂80mg/m2,d1,每3周1次,2周期后行放疗。结果:同步组和序贯组的总有效率分别为62.74%(64/102)和40.62%(39/96),差异有显著性(P<0.01);中位生存时间分别为21.6个月,18.4个月,同步组优于序贯组,差异无显著性;两组毒性差异相似。结论:三维适形放疗联合周剂量多西他赛同步治疗局部晚期非小细胞肺癌近期疗效较好,能明显提高患者的生活质量,不良反应能为患者耐受。 Objective: To evaluate the efficacy of docetaxel plus cisplatin chemotherapy with concurrent three dimensional radiotherapy (3DCRT) in patients with locally advanced non-small cell lung cancer (NSCLC). Methods: A total of 198 patients with locally advanced lung cancer were divided into the sequential group (102 cases) and the concurrent group (96 cases). Both groups received 3DCRT radiotherapy with a total dose of 70- 74Gy, 2.0-2.5Gy/fraction, 4-5 times per week. The patients in the concurrent group were treated with docetaxel (40mg/m^2) d1 and cisplatin (30mg/m^2) d1 weekly for 4-5 cycles. The patients in the sequential group were treated with docetaxel (60mg/m^2) d1 and cisplatin (80mg/m^2) d1 or carboplatin (300mg/m^2) d1. The cycle was repeated every 21 days. Radiotherapy was given after 2 cycles of chemotherapy. Results: The response rates of the concurrent group and the sequential group were 62.74% and 40.62%, respectively, with a statistical significance (P〈0.01). Median survival time was 21.6 months in the concurrent group and 18.4 months in the sequential group. The side effects in both groups were similar. Conclusion: 3DCRT combined with concur- rent docetaxel plus cisplatin chemotherapy is well tolerated and can improve the quality of life in most patients with locally advanced NSCLC.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2008年第22期1269-1271,共3页 Chinese Journal of Clinical Oncology
关键词 多西他赛 化疗 顺铂 非小细胞肺癌 三维适形放疗 Docetaxel Chemotherapy Cisplatin Non-small cell lung cancer Three dimensional conformal radiotherapy
  • 相关文献

参考文献8

  • 1Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998[J]. CA CancerJ Clin, 1998, 48(1): 6-29.
  • 2周际昌.实用肿瘤内科学[M].第二版.北京:人民卫生出版社,2005,431-439.
  • 3郝学志,张湘茹,孙燕,多西他赛临床研究协作组.国产多西他赛治疗乳腺癌和非小细胞肺癌的临床观察[J].中国肿瘤临床,2005,32(18):1064-1066. 被引量:24
  • 4吕纪马,王绿化.放射治疗同步应用紫杉醇治疗局部晚期非小细胞肺癌的进展[J].中华放射肿瘤学杂志,2004,13(4):312-315. 被引量:31
  • 5Granville CA, Derails PA. An overview of lung cancer genomics and proteomics[]]. Am J Respir Cell Mol Biol, 2005, 32(3): 169-176.
  • 6RosenmanJG, HaUeJS ,Socinski MA ,et al . High-dose conform mal radiotherapy for treatment of stage Ⅲ A/Ⅲ B non-small-cell lung cancer : technical issues and results of a phase Ⅰ / Ⅱ trial[]]. IntJ Radiat Oncol Biol Phys, 2002, 54(2): 348-356.
  • 7Curran WJ, Scott CB, Langer CJ, et al. Long term benefit is observe dina phase Ⅲ comparison of sequential vs concurrent chemo radiation for patients with unresected stage Ⅲ NSCLC: RTOG9410. Proc Am Soc Clin Oncol, 2003, 22: 621-627.
  • 8Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies[J]. Cancer Radiother, 2004, 8 Suppl 1: S5-S105.

二级参考文献46

  • 1Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol in P388 cell line[J]. Proc Am Assoc Cancer Res, 1994, 35:385~389.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-cell Lung Cancer [J] N Engl J Med, 2002, 346(2): 92~98.
  • 3Frank V. Fossella, Russell DeVore. Randomized Phase Ⅲ Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens [J]. J Clin Onco, 2000, 18(12):2354~2362.
  • 4Shepherd FA, Fossella FV, Lynch T, et al. Docetaxel (Taxotere)shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase Ⅲ trials. Semin Oncol, 2001, 28(1 suppl 2):4~9.
  • 5Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure[]]. BrJ Cancer, 2002, 87(11):1210~1215.
  • 6Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group []]. J Clin Oncol, 1999, 17(5):1413~1424.
  • 7Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group[J].J Clin Oncol, 1999, 17(8):2341~2354.
  • 8Ravdin P, ErbanJ, Overmoyer B, et al. Phase Ⅲ comparison of docetaxel and paclitaxel in patients with metastatic breast cancer [J]. EurJ Cancer, 2003, 1(suppl 5):201~205.
  • 9Choy H, Devore RE , Hande KR. A phase Ⅱ study of paclitaxel,carboplatin and concurrent hyperfranction radiotherapy for locally advanced inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys,2000,47: 931-937.
  • 10Ratanatharthorn V , Lorvidhaya V , Maoleekoonpairioj S. Phase Ⅱ trial of paclitaxel , carboplatin and concurrent radiotherapy for locally advanced no-small cell lung cancer. Lung Cancer , 2001,31: 257-265 .

共引文献52

同被引文献201

引证文献23

二级引证文献159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部